Browse > Article
http://dx.doi.org/10.5483/BMBRep.2018.51.11.180

STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells  

Jang, Hui-Ju (Department of Bioscience and Biotechnology, Konkuk University)
Bak, Yesol (Department of Bioscience and Biotechnology, Konkuk University)
Pham, Thu-Huyen (Department of Bioscience and Biotechnology, Konkuk University)
Kwon, Sae-Bom (Department of Bioscience and Biotechnology, Konkuk University)
Kim, Bo-Yeon (World Class Institute, Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology)
Hong, JinTae (College of Pharmacy and Medical Research Center, Chungbuk National University)
Yoon, Do-Young (Department of Bioscience and Biotechnology, Konkuk University)
Publication Information
BMB Reports / v.51, no.11, 2018 , pp. 596-601 More about this Journal
Abstract
Colon cancer is one of the most lethal and common malignancies worldwide. STK899704, a novel synthetic agent, has been reported to exhibit anticancer effects towards numerous cancer cells. However, the effect of STK899704 on the biological properties of colon cancer, including cancer cell migration and cancer stem cells (CSCs), remains unknown. Here, we examined the inhibitory effect of STK899704 on cell migration and CSC stemness. In the wound healing assay, STK899704 significantly inhibited the motility of colon cancer cells. Furthermore, STK899704 downregulated the mRNA expression levels of the cell migration mediator focal adhesion kinase (FAK). STK899704 also suppressed mitogen-activated protein kinase kinase and extracellular signal-regulated kinase, which are downstream signaling molecules of FAK. Additionally, STK899704 inhibited stemness gene expression and sphere formation in colon cancer stem cells. These results suggest that STK899704 can be used to treat human colon cancer.
Keywords
Cancer stem cell; Colon cancer; Focal adhesion kinase; Migration; STK899704;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Siegel R, Naishadham D and Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62, 283-298   DOI
2 Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380, 2095-2128   DOI
3 Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90   DOI
4 Bak Y, Kwon T, Bak IS, Hong J, Yu DY and Yoon DY (2016) IL-32theta inhibits stemness and epithelialmesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget 7, 7307-7317
5 Merika E, Saif MW, Katz A, Syrigos K and Morse M (2010) Review. Colon cancer vaccines: an update. In Vivo 24, 607-628
6 Bonnet D and Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-737   DOI
7 Jordan CT (2009) Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4, 203-205   DOI
8 Lessard J and Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260   DOI
9 Lee HE, Kim JH, Kim YJ et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104, 1730-1738   DOI
10 Gao XM, Zhang R, Dong QZ and Qin LX (2016) Properties and feasibility of using cancer stem cells in clinical cancer treatment. Cancer Biol Med 13, 489-495   DOI
11 Vinogradov S and Wei X (2012) Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7, 597-615   DOI
12 Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4, 253-265   DOI
13 Zhou J and Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5, 65-71   DOI
14 Sakchaisri K, Kim SO, Hwang J et al (2017) Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One 12, e0173311   DOI
15 Gialeli C, Theocharis AD and Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27   DOI
16 Liang W, Lai Y, Zhu M, Huang S, Feng W and Gu X (2016) Combretastatin A4 regulates proliferation, migration, invasion, and apoptosis of thyroid cancer cells via PI3K/Akt signaling pathway. Med Sci Monit 22, 4911-4917   DOI
17 McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG and Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5, 505-515   DOI
18 Goldman RD (1971) The role of three cytoplasmic fibers in BHK-21 cell motility. I. Microtubules and the effects of colchicine. J Cell Biol 51, 752-762   DOI
19 Pastrana E, Silva-Vargas V and Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8, 486-498   DOI
20 Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-3988   DOI
21 Han YS, Lee JH and Lee SH (2015) Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. Mol Med Rep 12, 3446-3452   DOI
22 Mu Y, Zou H, Chen B, Fan Y and Luo S (2017) FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. Biomed Pharmacother 90, 548-554   DOI
23 Wang YJ, Zhang ZF, Fan SH et al (2017) MicroRNA-433 inhibits oral squamous cell carcinoma cells by targeting FAK. Oncotarget 8, 100227-100241
24 Suva ML, Riggi N, Stehle JC et al (2009) Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69, 1776-1781   DOI
25 Deramaudt TB, Dujardin D, Noulet F et al (2014) Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes. PLoS One 9, e92059   DOI
26 Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF and Giancotti FG (2009) Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 119, 252-266
27 Schlaepfer DD, Mitra SK and Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692, 77-102   DOI
28 Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T and Moriwaki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351, 820-824   DOI
29 Kim WT and Ryu CJ (2017) Cancer stem cell surface markers on normal stem cells. BMB Rep 50, 285-298   DOI
30 Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB and Farrar WL (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98, 756-765   DOI
31 Bak Y, Kang JW, Kim MS et al (2014) IL-32theta downregulates CCL5 expression through its interaction with PKCdelta and STAT3. Cell Signal 26, 3007-3015   DOI
32 Bak Y, Ham S, Baatartsogt O et al (2013) A1E inhibits proliferation and induces apoptosis in NCI-H460 lung cancer cells via extrinsic and intrinsic pathways. Mol Biol Rep 40, 4507-4519   DOI